1. Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
- Author
-
Han N, Oh JM, and Kim IW
- Subjects
- Acids, Carbocyclic adverse effects, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Guanidines adverse effects, Humans, Infant, Infant, Newborn, Internet, Male, Middle Aged, Odds Ratio, Oseltamivir adverse effects, Patient Participation, Pyrans adverse effects, Risk Factors, Sialic Acids adverse effects, United States, United States Food and Drug Administration, Young Adult, Zanamivir adverse effects, Adverse Drug Reaction Reporting Systems, Antiviral Agents adverse effects, Influenza, Human drug therapy, Neuraminidase antagonists & inhibitors
- Abstract
The recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the analysis were oseltamivir, peramivir, zanamivir, and laninamivir. Disproportionality was analyzed using the proportional reporting ratio (PRR), the reporting odds ratio (ROR), and the information component (IC) methods. In total, 16729 AEs from 4598 patients and 575 AEs from 440 patients in the FAERS and WebMD, respectively, were included in the analysis. In the FAERS, AEs were more common among those who were younger (<19 years) for zanamivir, while for those who were older (>65 years) for peramivir. A disproportionality analysis showed that signals for vomiting and hallucinations were detected in younger patients given oseltamivir, while an abnormal hepatic function, cardiac failure, shock, and cardio-respiratory arrest were detected in older patients given peramivir. Psychiatric disorders were most common in younger and older patients, while gastrointestinal disorders were most common in adult given oseltamivir in the WebMD. Adverse symptoms related to NAIs varied and depended on the drugs used and the age of the patient.
- Published
- 2020
- Full Text
- View/download PDF